NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity
NetraMark Holdings (OTCQB: AINMF) has partnered with Pentara Corporation to launch an AI-powered site intelligence tool for enhancing clinical trial integrity. The collaboration introduces a novel system that calculates a Paradox Risk score to detect anomalous participant behavior and site-level irregularities using pre-randomization data.
The partnership combines NetraMark's AI technology with Pentara's expertise in clinical data analysis, particularly in degenerative diseases. The tool integrates information-theoretic variability, singleton occurrence frequencies, and co-association penalties to identify potential data integrity issues that could affect trial outcomes.
This strategic alliance aims to enable proactive risk mitigation, implement scalable site monitoring with real-time alerts, and enhance confidence in efficacy outcomes across heterogeneous clinical trials.
NetraMark Holdings (OTCQB: AINMF) ha stretto una collaborazione con Pentara Corporation per lanciare uno strumento di intelligenza artificiale per migliorare l'integrità dei trial clinici. Questa collaborazione introduce un sistema innovativo che calcola un Paradox Risk score per individuare comportamenti anomali dei partecipanti e irregolarità a livello del sito, utilizzando dati pre-randomizzazione.
La partnership unisce la tecnologia AI di NetraMark con l'esperienza di Pentara nell'analisi dei dati clinici, in particolare nelle malattie degenerative. Lo strumento integra la variabilità basata sulla teoria dell'informazione, le frequenze di occorrenza singole e le penalità di co-associazione per identificare potenziali problemi di integrità dei dati che potrebbero influenzare i risultati del trial.
Questa alleanza strategica mira a consentire una mitigazione proattiva del rischio, implementare un monitoraggio scalabile dei siti con avvisi in tempo reale e aumentare la fiducia nei risultati di efficacia attraverso trial clinici eterogenei.
NetraMark Holdings (OTCQB: AINMF) se ha asociado con Pentara Corporation para lanzar una herramienta de inteligencia de sitios impulsada por IA que mejora la integridad de los ensayos clínicos. La colaboración presenta un sistema novedoso que calcula un Paradox Risk score para detectar comportamientos anómalos de los participantes y irregularidades a nivel de sitio utilizando datos previos a la aleatorización.
La asociación combina la tecnología de IA de NetraMark con la experiencia de Pentara en análisis de datos clínicos, especialmente en enfermedades degenerativas. La herramienta integra variabilidad basada en la teoría de la información, frecuencias de ocurrencia de elementos únicos y penalizaciones por co-asociación para identificar posibles problemas de integridad de datos que podrían afectar los resultados del ensayo.
Esta alianza estratégica busca permitir una mitigación proactiva del riesgo, implementar monitoreo escalable de sitios con alertas en tiempo real y aumentar la confianza en los resultados de eficacia en ensayos clínicos heterogéneos.
NetraMark Holdings (OTCQB: AINMF)는 임상 시험의 무결성을 강화하기 위해 Pentara Corporation와 협력하여 AI 기반 사이트 인텔리전스 도구를 출시했습니다. 이 협력은 무작위 배정 전 데이터를 사용하여 이상 참가자 행동과 사이트 수준의 이상 징후를 감지하는 Paradox Risk 점수를 계산하는 새로운 시스템을 도입합니다.
이번 파트너십은 NetraMark의 AI 기술과 Pentara의 임상 데이터 분석 전문성, 특히 퇴행성 질환 분야의 경험을 결합합니다. 이 도구는 정보 이론적 변동성, 단일 발생 빈도, 공동 연관 패널티를 통합하여 시험 결과에 영향을 미칠 수 있는 데이터 무결성 문제를 식별합니다.
이 전략적 제휴는 위험을 사전에 완화하고, 실시간 알림이 가능한 확장 가능한 사이트 모니터링을 구현하며, 이질적인 임상 시험 전반에 걸쳐 효능 결과에 대한 신뢰를 높이는 것을 목표로 합니다.
NetraMark Holdings (OTCQB : AINMF) s'est associé à Pentara Corporation pour lancer un outil d'intelligence de site alimenté par l'IA visant à renforcer l'intégrité des essais cliniques. Cette collaboration introduit un système novateur qui calcule un score de risque Paradox pour détecter les comportements anormaux des participants et les irrégularités au niveau des sites en utilisant les données pré-randomisation.
Le partenariat combine la technologie IA de NetraMark avec l'expertise de Pentara en analyse de données cliniques, notamment dans les maladies dégénératives. L'outil intègre la variabilité basée sur la théorie de l'information, les fréquences d'occurrence des singletons et les pénalités de co-association pour identifier d'éventuels problèmes d'intégrité des données pouvant affecter les résultats des essais.
Cette alliance stratégique vise à permettre une atténuation proactive des risques, à mettre en œuvre une surveillance évolutive des sites avec des alertes en temps réel, et à renforcer la confiance dans les résultats d'efficacité à travers des essais cliniques hétérogènes.
NetraMark Holdings (OTCQB: AINMF) hat sich mit Pentara Corporation zusammengetan, um ein KI-gestütztes Site-Intelligence-Tool zur Verbesserung der Integrität klinischer Studien einzuführen. Die Zusammenarbeit bringt ein neuartiges System hervor, das einen Paradox Risk Score berechnet, um anomales Teilnehmerverhalten und Unregelmäßigkeiten auf Standortebene anhand von Daten vor der Randomisierung zu erkennen.
Die Partnerschaft verbindet NetraMarks KI-Technologie mit Pentaras Expertise in der klinischen Datenanalyse, insbesondere bei degenerativen Erkrankungen. Das Tool integriert informationstheoretische Variabilität, Häufigkeiten einzelner Vorkommnisse und Koassoziationsstrafen, um potenzielle Probleme mit der Datenintegrität zu identifizieren, die die Studienergebnisse beeinflussen könnten.
Diese strategische Allianz zielt darauf ab, eine proaktive Risikominderung zu ermöglichen, skalierbares Standortmonitoring mit Echtzeitwarnungen zu implementieren und das Vertrauen in Wirksamkeitsergebnisse über heterogene klinische Studien hinweg zu stärken.
- Partnership enhances clinical trial integrity through advanced AI-driven anomaly detection
- Tool enables early detection of data integrity issues before they affect trial outcomes
- Real-time alerts and targeted audit capabilities across trials
- Expansion of NetraMark's AI technology into pre-trial site selections and active trial site reporting
- Implementation complexity of the new AI system may require significant training and adaptation
- Potential regulatory scrutiny over AI-driven decision-making in clinical trials
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement.
NetraMark, in collaboration with Pentara, will be co-branding and launching a novel site intelligence tool as part of a joint initiative to enhance clinical trial integrity through advanced AI-driven anomaly detection. The tool integrates information-theoretic variability, singleton occurrence frequencies, and co-association penalties to derive a Paradox Risk score for anomaly detection at the participant level. This enables the detection of anomalous participants and assessment of site-level irregularities. The framework identifies site-level integrity and anomalous risks using only pre-randomization data. Undetected data integrity issues can distort efficacy signals and threaten the validity of study conclusions.
Pentara has established itself as an industry leader and innovator in degenerative diseases. Pentara’s decision to partner with NetraMark highlights its determination to leverage the latest innovative technologies to provide its clients with powerful analytical insights that drive clinical decision-making.
“We are excited to partner with NetraMark, which focuses on the responsible use of AI in clinical trials, and the implementation of regulatory-aligned AI strategies that provide data-driven insights to guide success throughout a trial. Applying this innovative technology demonstrates our commitment to providing high-quality, efficient solutions to our clients that accelerate medical research,” commented Suzanne Hendrix, PhD, CEO at Pentara Corporation.
“This partnership marks a significant milestone for NetraMark as we expand opportunities to leverage our AI technology to inform sponsors of potential areas of improvement in their trial design, beyond participant eligibility criteria and into earlier stages of development, such as pre-trial site selections and active trial site reporting,” shared Dr. Joseph Geraci, PhD, Founder, CTO/CSO at NetraMark.
NetraMark’s contributions are expected to enable Pentara to proactively mitigate early risks and implement scalable monitoring of sites with real-time alerts and targeted audits across trials. This collaboration is intended to enhance confidence in efficacy outcomes with adaptability to heterogeneous clinical trials and will focus on generating validated and explainable insights to optimize future trial design.
About NetraMark
NetraMark is a company focused on being a leader in the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the Pharmaceutical industry. Its product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows NetraMark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that NetraMark can work with much smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.
For further details on the Company please see the Company’s publicly available documents filed on the System for Electronic Document Analysis and Retrieval+ (SEDAR+).
For more NetraMark information, see the company’s website and follow NetraMark on LinkedIn.
About Pentara
Pentara offers statistical and data analysis services to the pharmaceutical and biotechnology industries. Pentara focuses on providing high-quality, efficient, and compliant solutions, and aims to be a trusted partner to its clients, providing innovative solutions to improve drug development outcomes
Pentara statisticians are world leaders in innovative study design and analysis, ensuring that effective treatments succeed sooner and ineffective ones fail faster. Pentara’s quick turnaround time and independent confirmation provide companies with trusted statistical analyses for strategic decision-making. Pentara provides a statistical voice throughout the clinical trial process by bringing a statistical perspective to the process from study design and data management through report finalization.
Pentara’s clients are primarily small pharmaceutical and biotech companies, but also include academic groups, medium and large pharmaceutical companies. Projects include phase 1- phase 4 clinical trials. Pentara provides a strategic balance between cost and sample size by helping its clients reduce error in order to increase the efficiency of clinical trials.
For more Pentara information, see the company’s website
Forward-Looking Statements
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation including statements regarding the potential benefits of the partnership with Pentara, the ability of NetraMark's AI technology to inform sponsors of areas of improvement in trial design, the potential enhancement of confidence in efficacy outcomes, the generation of validated and explainable insights to optimize future trial design, the development and commercialization of the site intelligence tool, which are based upon NetraMark’s current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. The forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results of the Company or industry results to differ materially from future results, performance or achievements. Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, NetraMark does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for NetraMark to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements as set out in the materials we file with applicable Canadian securities regulatory authorities on SEDAR+ at www.sedarplus.ca including our Management’s Discussion and Analysis for the year ended September 30, 2024. These risk factors and other factors could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Contact Information:
Swapan Kakumanu - CFO | swapan@netramark.com | 403-681-2549
FAQ
What is the purpose of NetraMark's (AINMF) partnership with Pentara?
How does NetraMark's new clinical trial tool work?
What benefits does the NetraMark-Pentara partnership bring to clinical trials?
When will NetraMark's (AINMF) site intelligence tool be implemented?
How will this partnership affect NetraMark's (AINMF) market position?
